---
schema_version: "secwatch.filing_event.v1"
accession: "0001654954-22-015138"
form_type: "8-K"
ticker: "PTN"
cik: "0000911216"
company_name: "PALATIN TECHNOLOGIES INC"
filed_at: "2022-11-14T23:59:59+00:00"
generated_at: "2026-06-21T21:57:08.983603+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Palatin Q1 FY2023 net loss $8.3M; Vyleesi revenue up 445% YoY; PL9643 topline Q2 2023

## Summary
- Net loss of $8.3M ($0.86/share) vs $7.1M ($0.75/share) in prior year quarter.
- Vyleesi net product revenue $869,654, up 445% YoY; prescriptions dispensed up 17% QoQ.
- Phase 3 PL9643 for dry eye: DMC recommends 350-patient study; topline data expected Q2 2023.
- Phase 2 oral PL8177 for ulcerative colitis commenced; interim analysis Q1 2023, topline Q3 2023.
- Cash $21.2M as of Sep 30; closed $10M offering in Nov 2022; operating cash runway through CY 2023.

## SEC filing metadata
- accession: 0001654954-22-015138
- form_type: 8-K
- ticker: PTN
- cik: 0000911216
- company_name: PALATIN TECHNOLOGIES INC
- filed_at: 2022-11-14T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/911216/000165495422015138/0001654954-22-015138-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/911216/000165495422015138/ptn_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001654954-22-015138
- JSON: https://secwatch.observer/filing/0001654954-22-015138.json
- Plain text: https://secwatch.observer/filing/0001654954-22-015138.txt

## Key facts
- Earnings Releases
  PALATIN TECHNOLOGIES INC reported fiscal first quarter ended September 30, 2022 results: revenue $2.3 million, net income $8.3 million, EPS $(0.86) per common share.
  - Period: fiscal first quarter ended September 30, 2022
  - Revenue: $2.3 million
  - Net income: $8.3 million
  - EPS: $(0.86) per common share
  - Result: reported results
  source text: as of June 30, 2022. · Vyleesi® (bremelanotide injection) for the treatment of Hypoactive Sexual Desire Disorder (HSDD): Gross product sales to pharmacy distributors amounted to $2.3 million, while net product revenue increased 13% and prescriptions dispensed increased 17%, over the prior quarter. 1 Business Highlights and Recent Updates · Anti-Inflammatory /
  evidence_url: https://www.sec.gov/Archives/edgar/data/911216/000165495422015138/0001654954-22-015138-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.